Hyalvisc Injection contains Sodium Hyaluronate 8 mg/ml, a high molecular weight glycosaminoglycan used primarily for viscosupplementation in the management of osteoarthritis-related joint pain. Sodium Hyaluronate is a naturally occurring component of synovial fluid, contributing to its viscoelastic properties, lubrication, and shock absorption within the joint space. Hyalvisc Injection is administered via intra-articular injection to restore the viscoelasticity of synovial fluid, thereby improving joint mobility and reducing pain in patients with mild to moderate osteoarthritis, particularly of the knee. The product is indicated for patients who have not responded adequately to conservative treatments such as analgesics, nonsteroidal anti-inflammatory drugs (NSAIDs), or physical therapy. By supplementing the deficient or degraded endogenous hyaluronic acid, Hyalvisc Injection helps to protect cartilage, reduce inflammation, and enhance joint function. The treatment regimen typically involves a series of injections administered at weekly intervals, with clinical benefits observed within weeks and lasting several months. Hyalvisc Injection is generally well tolerated, with adverse effects limited to mild local reactions such as transient pain, swelling, or erythema at the injection site. It should be used with caution in patients with known hypersensitivity to hyaluronate preparations or in cases of joint infection.